Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (23736)	5/22/2007 10:45:10 AM
From: Robohogs	Read Replies (2) \| Respond to of 52153

Peter, Are you noticing how some of the stocks pinned to strikes last week are flying this week, mainly the very heavily shorted puppies? I am noticing this in MNTA and RPRX in bio-land, in the Alt-A players, in FMD, in Smith Micro, and a few others. Massive, massive up moves. MNTA $1 in barely more than a day, FMD $3, AHM $1+, RPRX just under $1, ARNA (not at a pin) but more modest move but on top of big move last week, IMB $3 or so. Jon

To: Biomaven who wrote (23736)	5/22/2007 1:28:38 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

>> ABC News last night was suggesting that this was a major drug disaster that yet again called into question the FDA's competency. << I meet a wide variety of individuals, crossing lots of society's corners. It is the GENERAL BELIEF, among those who I meet, that medicines are poisons with benefit. But when an alarmist goes all Politico-Hollywood on us? Poof, it's lawsuit time, brains in neutral! I worked at a pharma, in R&D. The entire story was about finding good medicines. It's not about a bunch of cloaked mad men, huddled around steamy cauldrons and driven by marketing managers. And FDA? The agency serves a dual purpose.... it controls the gate to medical innovation (given the contribution of U.S. markets to total), and it must assure safety. Tough job, and FDA has set the performance standard for a slug of years. In recent years, the U.S. regulatory environment is looking a tad irrationally tight. We are going out of our way to make our markets unattractive, and to simultaneously enrich plaintiff's attorneys.